Co-Diagnostics (NASDAQ:CODX) versus NewGenIvf Group (NASDAQ:NIVF) Financial Survey

NewGenIvf Group (NASDAQ:NIVF) and Co-Diagnostics (NASDAQ:CODX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, valuation, earnings and risk.

Institutional and Insider Ownership

66.2% of NewGenIvf Group shares are held by institutional investors. Comparatively, 15.0% of Co-Diagnostics shares are held by institutional investors. 31.8% of NewGenIvf Group shares are held by company insiders. Comparatively, 5.4% of Co-Diagnostics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares NewGenIvf Group and Co-Diagnostics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
NewGenIvf Group	N/A	N/A	N/A
Co-Diagnostics	-6,760.63%	-164.92%	-141.15%

Analyst Ratings

This is a summary of recent ratings for NewGenIvf Group and Co-Diagnostics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NewGenIvf Group	1	0	0	0	1.00
Co-Diagnostics	1	2	1	0	2.00

Co-Diagnostics has a consensus target price of $67.50, suggesting a potential upside of 640.94%. Given Co-Diagnostics’ stronger consensus rating and higher possible upside, analysts clearly believe Co-Diagnostics is more favorable than NewGenIvf Group.

Volatility and Risk

NewGenIvf Group has a beta of 0.04, meaning that its stock price is 96% less volatile than the S&P 500. Comparatively, Co-Diagnostics has a beta of 1.26, meaning that its stock price is 26% more volatile than the S&P 500.

Earnings & Valuation

This table compares NewGenIvf Group and Co-Diagnostics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NewGenIvf Group	$4.73 million	0.04	$9.88 million	N/A	N/A
Co-Diagnostics	$718,166.00	45.69	-$46.90 million	($15.77)	-0.58

NewGenIvf Group has higher revenue and earnings than Co-Diagnostics.

Summary

NewGenIvf Group beats Co-Diagnostics on 7 of the 12 factors compared between the two stocks.

About NewGenIvf Group

NewGenIVF Group Ltd. operates as an assisted reproductive services provider. It focuses on providing fertility treatments to fulfil the dreams of building families. The firm offers in-vitro fertilization treatment service, comprising traditional IVF and egg donation, and surrogacy and ancillary caring services. The company was founded by Siu Wing Fung and Fong Hei Yue on January 16, 2019 and is headquartered in Bangkok, Thailand.

About Co-Diagnostics

Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.